RECRUITING

Triage Survey for Neurology Research Eligibility

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.

Official Title

Triage Survey for Neurology Research Eligibility

Quick Facts

Study Start:2023-06-02

Study Completion:2027-06-02

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06104852

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Participant and study partner (when applicable) have signed an ICF prior to study-specific procedures being performed. * Participant and study partner (when applicable) are at least 18 years old.	* Participant lacks the language skills or cognitive ability to understand the screening process. * Participant is pregnant, breast-feeding, or planning to become pregnant. * History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results. * Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on Columbia-Suicide Severity Rating Scale questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening. * Moderate or severe substance use disorder within 90 days prior to screening, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant. * Any condition that in the investigator's opinion makes a participant unsuitable for the study. * Currently employed by Adams Clinical or a first-degree relative of an employee working on this study.

Inclusion Criteria

Exclusion Criteria

* Participant and study partner (when applicable) have signed an ICF prior to study-specific procedures being performed.
* Participant and study partner (when applicable) are at least 18 years old.

* Participant lacks the language skills or cognitive ability to understand the screening process.
* Participant is pregnant, breast-feeding, or planning to become pregnant.
* History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results.
* Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on Columbia-Suicide Severity Rating Scale questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening.
* Moderate or severe substance use disorder within 90 days prior to screening, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant.
* Any condition that in the investigator's opinion makes a participant unsuitable for the study.
* Currently employed by Adams Clinical or a first-degree relative of an employee working on this study.

Contacts and Locations

Study Contact

Sarah J Starling, PhD

CONTACT

6177448542

sstarling@adamsclinical.com

Study Locations (Sites)

Copley Clinical

Boston, Massachusetts, 02116

United States

Adams Clinical

Watertown, Massachusetts, 02472

United States

Berman Clinical

New York, New York, 10029

United States

Collaborators and Investigators

Sponsor: Adams Clinical

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-02

Study Completion Date2027-06-02

Study Record Updates

Study Start Date2023-06-02

Study Completion Date2027-06-02

Terms related to this study

Additional Relevant MeSH Terms

Alzheimer Disease